search
Back to results

Thymus Transplantation Dose in DiGeorge #932

Primary Purpose

DiGeorge Anomaly, DiGeorge Syndrome, Complete DiGeorge Anomaly

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Cultured Thymus Tissue Implantation (CTTI)
Cultured Thymus Tissue Implantation with Parathyroid Transplantation
Sponsored by
Enzyvant Therapeutics GmBH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for DiGeorge Anomaly focused on measuring Thymus Transplantation, DiGeorge Syndrome, DiGeorge Anomaly, Athymia, Parathyroid Transplantation, Hypocalcemia, Hypoparathyroidism, Low T cell numbers, Immunoreconstitution, Immunodeficiency, Complete DiGeorge, Complete DiGeorge Anomaly, Typical DiGeorge, Cultured Thymus Tissue Implantation (CTTI)

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Thymus Transplant Inclusion Criteria:

  • A parent or guardian of the DGS subject signed the consent form.
  • Medical screening was completed.
  • For a diagnosis of DGS, the subject had to have one of the following:

    • Congenital heart disease;
    • Hypocalcemia requiring replacement;
    • 22q11.2 hemizygosity or 10p13 hemizygosity;
    • CHARGE association or CHD7 mutation;
    • A subject with abnormal ears whose mother had diabetes (type I, type II, or gestational).
  • To meet the criteria of typical complete DiGeorge Anomaly (cDGA), the subject had to have either:

    • Circulating CD3+ T cell count by flow cytometry < 50/mm3 OR
    • Circulating CD3+ T cells that were also positive for Cluster of Differentiation 45RA (CD45RA)+ CD62L+ and were < 50/mm3 or less than 5% of total T cells.

Thymus Transplant Exclusion Criteria:

  • Had heart surgery less than 4 weeks prior to projected implant date;
  • Heart surgery anticipated within 3 months after the proposed time of implantation;
  • Present or past lymphadenopathy;
  • Rash associated with T cell infiltration of the dermis and epidermis;
  • Rejection by the surgeon or anesthesiologist as surgical candidate;
  • Lack of sufficient muscle tissue to accept a transplant of 4 g/m2 body surface area (BSA) or 0.2 g/kg subject bodyweight;
  • Had human immunodeficiency virus (HIV) infection;
  • Had prior attempts at immune reconstitution, such as bone marrow transplant or previous thymus transplantation;
  • Ventilator support or positive pressure support: Subjects had to be off ventilator or other pressure support such as continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP) support for 2 weeks prior to enrollment. If the subject was enrolled and was placed back on ventilator or pressure support, the subject had to be able to be weaned off and remain off ventilator or pressure support for 2 weeks. If the subject could not be successfully weaned off ventilator or pressure support, the subject was to be withdrawn from the study.

Additional Inclusion Criteria for Parathyroid Transplant Recipient:

  • 2 tests in patient showing: intact parathyroid hormone (PTH) < 5 pg/ml when ionized calcium < 1.1 mmol/L
  • All inclusion criteria for thymus transplant must be met
  • 2 involved parents

Exclusion for Parathyroid Transplant Recipient:

  • Parents do not meet enrollment criteria.
  • Parent(s) decline to be parathyroid donor(s).

Parental Parathyroid Donor Inclusion:

  • > 18 years old
  • Answers all questionnaire items and meets safety screening criteria
  • Normal serum calcium
  • Normal PTH function
  • HLA typing consistent with parentage
  • Parent chosen for donation will share HLA-DR allele in thymus donor; if not applicable, then either parent will be selected (if meet all other criteria).
  • Must not be on anticoagulation or can come off for donation/transplantation

Parental Parathyroid Donor Exclusion:

  • Donor is only living involved parent or caretaker of the recipient
  • Hypoparathyroidism - low parathyroid hormone (PTH) in presence of low serum calcium and high serum phosphate
  • Hyperparathyroidism (or history of) - elevated PTH in presence of high serum calcium and low serum phosphate
  • History of cancer
  • Evidence of any of following: HIV-1, HIV-2, HTLV-1, HTLV-2, syphilis, hepatitis B, hepatitis C, West Nile virus, or Trypanosoma Cruzi (Chagas disease)
  • Elevated AST, ALT, alkaline phosphatase > 3 times upper limit of normal
  • History including receipt of a xenograft or risk factors for SARS, Mad Cow - Disease or smallpox. Note: if parent has Mad Cow Disease risk factors (but not active disease), parent(s) may give permission for transplantation.
  • CMV positive urine
  • Positive CMV IgM antibodies
  • Positive IgM anti-EBV VCA
  • On blood thinners and cannot stop for the parathyroid donation
  • Elevated PT or PTT (> ULN)
  • Platelets < 100,000
  • Positive Toxoplasma IgM
  • The donor will receive a history and physical; may be excluded based on PI's medical judgment
  • Hemoglobin < 9 g/dl
  • Infectious lesion on head or neck
  • Goiter on ultrasound
  • Abnormal fiberoptic laryngoscopy of vocal cords
  • Pregnancy
  • Positive HSV IgG is not an exclusion; however, post transplantation prophylaxis is needed
  • Positive VZV IgG is not an exclusion; however, post transplantation prophylaxis is needed
  • Medical concern of otolaryngologist
  • Concern by medical psychologist or social worker. Parents are interviewed together and separately regarding following areas: medical history; health habits; substance use; relationships and support; education/work history; mental status/psychological history; readiness for donation.
  • Questionnaire (safety screening) responses can lead to exclusion.

Biological Mother of DiGeorge Subject Inclusion Criteria:

  • Competent to provide consent
  • Willing to provide blood for testing (No other inclusion/exclusion for mother)

Sites / Locations

  • Duke University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Cultured Thymus Tissue Implantation w Parathyroid Transplant

Cultured Thymus Tissue Implantation

Arm Description

Cultured Thymus Tissue Implantation With Parathyroid Tissue Transplantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation with parathyroid transplantation, if eligible. No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient. There was a one time administration of the cultured thymus tissue and parathyroid tissue.

Cultured Thymus Tissue Implantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation (CTTI) only. No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient. There was a one time administration of the cultured thymus tissue. .

Outcomes

Primary Outcome Measures

Survival at 1 Year Post-CTTI
Survival at 1 year post CTTI was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.

Secondary Outcome Measures

Survival at 2 Years Post-CTTI
Survival at 2 years post CTTI was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.
Immune Reconstitution Efficacy - CD3 T Cells
The development of total CD3 T cells at one year as measured using flow cytometry
Immune Reconstitution Efficacy - CD4 T Cells
The development of total CD4 T cells at one year as measured using flow cytometry
Immune Reconstitution Efficacy - CD8 T Cells
The development of total CD8 T cells at one year as measured using flow cytometry
Immune Reconstitution Efficacy - Naive CD4 T Cells
The development of naive CD4 T cells at one year as measured using flow cytometry
Immune Reconstitution Efficacy - Naive CD8 T Cells
The development of naïve CD8 T cells at one year as measured using flow cytometry.
Immune Reconstitution Efficacy - Response to Mitogens
The development of a T cell proliferative response to the mitogen phytohemagglutinin.
Thymus Allograft Biopsy
Evidence, on biopsy of the thymus tissue implanted in the recipient muscle, that shows the development of new T cells.

Full Information

First Posted
December 17, 2007
Last Updated
March 23, 2022
Sponsor
Enzyvant Therapeutics GmBH
Collaborators
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT00576836
Brief Title
Thymus Transplantation Dose in DiGeorge #932
Official Title
Dose Study of Thymus Transplantation in DiGeorge Anomaly, IND 9836, #932.1
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
September 2, 2004 (Actual)
Primary Completion Date
November 2010 (Actual)
Study Completion Date
December 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Enzyvant Therapeutics GmBH
Collaborators
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
One purpose of this study is to determine whether the amount of cultured thymus tissue implanted into DiGeorge anomaly infants has any effect on the immune outcome. Another purpose of this study is to determine whether parental parathyroid transplantation (in addition to cultured thymus tissue implantation (CTTI) can help both the immune and the calcium problems in DiGeorge infants with hypocalcemia. [Funding Source - FDA Office of Orphan Products Development (OOPD)]
Detailed Description
DiGeorge anomaly is a congenital disorder in which infants are born with defects of the thymus, heart, and parathyroid gland. Complete DiGeorge Anomaly is usually fatal within the first two years of life. This trial evaluates the role of cultured thymus tissue dose in cultured thymus tissue implantation (CTTI) in complete (typical) DiGeorge anomaly infants, and continues safety assessments. DiGeorge infants who have successful CTTIs but remain with hypoparathyroidism must go to the clinic for frequent calcium levels and to the hospital for calcium infusions; these infants are at risk for seizures from low calcium. Approximately ½ of infants with profound hypoparathyroidism will develop nephrocalcinosis. This protocol had a parental parathyroid transplant arm for complete DiGeorge infants with athymia and profound hypoparathyroidism.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
DiGeorge Anomaly, DiGeorge Syndrome, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
Keywords
Thymus Transplantation, DiGeorge Syndrome, DiGeorge Anomaly, Athymia, Parathyroid Transplantation, Hypocalcemia, Hypoparathyroidism, Low T cell numbers, Immunoreconstitution, Immunodeficiency, Complete DiGeorge, Complete DiGeorge Anomaly, Typical DiGeorge, Cultured Thymus Tissue Implantation (CTTI)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cultured Thymus Tissue Implantation w Parathyroid Transplant
Arm Type
Experimental
Arm Description
Cultured Thymus Tissue Implantation With Parathyroid Tissue Transplantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation with parathyroid transplantation, if eligible. No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient. There was a one time administration of the cultured thymus tissue and parathyroid tissue.
Arm Title
Cultured Thymus Tissue Implantation
Arm Type
Experimental
Arm Description
Cultured Thymus Tissue Implantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation (CTTI) only. No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient. There was a one time administration of the cultured thymus tissue. .
Intervention Type
Biological
Intervention Name(s)
Cultured Thymus Tissue Implantation (CTTI)
Other Intervention Name(s)
Thymus Tissue for Transplantation, CTTI
Intervention Description
Thymus tissue (from unrelated donor), thymus donor, and thymus donor's birth mother screened for safety. CTTI was done under general anesthesia. Cultured thymus tissue was implanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not >18 grams/m2 body surface area (1.0 grams/kg body weight). At time of CTTI, skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy was done to evaluate for thymopoiesis & graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-CTTI, subjects followed by immune evaluations, using blood samples.
Intervention Type
Other
Intervention Name(s)
Cultured Thymus Tissue Implantation with Parathyroid Transplantation
Other Intervention Name(s)
Thymus and Parathyroid Transplant, CTTI and Parathyroid Transplant
Intervention Description
Parental parathyroid donors screened for eligibility and safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most Human Leukocyte Antigens (HLA) alleles with thymus donor. Parathyroid harvest & transplant preferably done at same time as CTTI. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of CTTI.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced & placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
Primary Outcome Measure Information:
Title
Survival at 1 Year Post-CTTI
Description
Survival at 1 year post CTTI was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.
Time Frame
1 year post-CTTI
Secondary Outcome Measure Information:
Title
Survival at 2 Years Post-CTTI
Description
Survival at 2 years post CTTI was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.
Time Frame
2 years post-CTTI
Title
Immune Reconstitution Efficacy - CD3 T Cells
Description
The development of total CD3 T cells at one year as measured using flow cytometry
Time Frame
1 year post-CTTI
Title
Immune Reconstitution Efficacy - CD4 T Cells
Description
The development of total CD4 T cells at one year as measured using flow cytometry
Time Frame
1 year post-CTTI
Title
Immune Reconstitution Efficacy - CD8 T Cells
Description
The development of total CD8 T cells at one year as measured using flow cytometry
Time Frame
1 year post-CTTI
Title
Immune Reconstitution Efficacy - Naive CD4 T Cells
Description
The development of naive CD4 T cells at one year as measured using flow cytometry
Time Frame
1 year post-CTTI
Title
Immune Reconstitution Efficacy - Naive CD8 T Cells
Description
The development of naïve CD8 T cells at one year as measured using flow cytometry.
Time Frame
1 year post-CTTI
Title
Immune Reconstitution Efficacy - Response to Mitogens
Description
The development of a T cell proliferative response to the mitogen phytohemagglutinin.
Time Frame
1 year post-CTTI
Title
Thymus Allograft Biopsy
Description
Evidence, on biopsy of the thymus tissue implanted in the recipient muscle, that shows the development of new T cells.
Time Frame
2 to 3 months post-CTTI

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Thymus Transplant Inclusion Criteria: A parent or guardian of the DGS subject signed the consent form. Medical screening was completed. For a diagnosis of DGS, the subject had to have one of the following: Congenital heart disease; Hypocalcemia requiring replacement; 22q11.2 hemizygosity or 10p13 hemizygosity; CHARGE association or CHD7 mutation; A subject with abnormal ears whose mother had diabetes (type I, type II, or gestational). To meet the criteria of typical complete DiGeorge Anomaly (cDGA), the subject had to have either: Circulating CD3+ T cell count by flow cytometry < 50/mm3 OR Circulating CD3+ T cells that were also positive for Cluster of Differentiation 45RA (CD45RA)+ CD62L+ and were < 50/mm3 or less than 5% of total T cells. Thymus Transplant Exclusion Criteria: Had heart surgery less than 4 weeks prior to projected implant date; Heart surgery anticipated within 3 months after the proposed time of implantation; Present or past lymphadenopathy; Rash associated with T cell infiltration of the dermis and epidermis; Rejection by the surgeon or anesthesiologist as surgical candidate; Lack of sufficient muscle tissue to accept a transplant of 4 g/m2 body surface area (BSA) or 0.2 g/kg subject bodyweight; Had human immunodeficiency virus (HIV) infection; Had prior attempts at immune reconstitution, such as bone marrow transplant or previous thymus transplantation; Ventilator support or positive pressure support: Subjects had to be off ventilator or other pressure support such as continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP) support for 2 weeks prior to enrollment. If the subject was enrolled and was placed back on ventilator or pressure support, the subject had to be able to be weaned off and remain off ventilator or pressure support for 2 weeks. If the subject could not be successfully weaned off ventilator or pressure support, the subject was to be withdrawn from the study. Additional Inclusion Criteria for Parathyroid Transplant Recipient: 2 tests in patient showing: intact parathyroid hormone (PTH) < 5 pg/ml when ionized calcium < 1.1 mmol/L All inclusion criteria for thymus transplant must be met 2 involved parents Exclusion for Parathyroid Transplant Recipient: Parents do not meet enrollment criteria. Parent(s) decline to be parathyroid donor(s). Parental Parathyroid Donor Inclusion: > 18 years old Answers all questionnaire items and meets safety screening criteria Normal serum calcium Normal PTH function HLA typing consistent with parentage Parent chosen for donation will share HLA-DR allele in thymus donor; if not applicable, then either parent will be selected (if meet all other criteria). Must not be on anticoagulation or can come off for donation/transplantation Parental Parathyroid Donor Exclusion: Donor is only living involved parent or caretaker of the recipient Hypoparathyroidism - low parathyroid hormone (PTH) in presence of low serum calcium and high serum phosphate Hyperparathyroidism (or history of) - elevated PTH in presence of high serum calcium and low serum phosphate History of cancer Evidence of any of following: HIV-1, HIV-2, HTLV-1, HTLV-2, syphilis, hepatitis B, hepatitis C, West Nile virus, or Trypanosoma Cruzi (Chagas disease) Elevated AST, ALT, alkaline phosphatase > 3 times upper limit of normal History including receipt of a xenograft or risk factors for SARS, Mad Cow - Disease or smallpox. Note: if parent has Mad Cow Disease risk factors (but not active disease), parent(s) may give permission for transplantation. CMV positive urine Positive CMV IgM antibodies Positive IgM anti-EBV VCA On blood thinners and cannot stop for the parathyroid donation Elevated PT or PTT (> ULN) Platelets < 100,000 Positive Toxoplasma IgM The donor will receive a history and physical; may be excluded based on PI's medical judgment Hemoglobin < 9 g/dl Infectious lesion on head or neck Goiter on ultrasound Abnormal fiberoptic laryngoscopy of vocal cords Pregnancy Positive HSV IgG is not an exclusion; however, post transplantation prophylaxis is needed Positive VZV IgG is not an exclusion; however, post transplantation prophylaxis is needed Medical concern of otolaryngologist Concern by medical psychologist or social worker. Parents are interviewed together and separately regarding following areas: medical history; health habits; substance use; relationships and support; education/work history; mental status/psychological history; readiness for donation. Questionnaire (safety screening) responses can lead to exclusion. Biological Mother of DiGeorge Subject Inclusion Criteria: Competent to provide consent Willing to provide blood for testing (No other inclusion/exclusion for mother)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
M. Louise Markert, MD, PhD
Organizational Affiliation
Duke University Medical Center, Pediatrics, Allergy & Immunology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
18155964
Citation
Chinn IK, Devlin BH, Li YJ, Markert ML. Long-term tolerance to allogeneic thymus transplants in complete DiGeorge anomaly. Clin Immunol. 2008 Mar;126(3):277-81. doi: 10.1016/j.clim.2007.11.009. Epub 2007 Dec 26.
Results Reference
background
PubMed Identifier
12702512
Citation
Markert ML, Sarzotti M, Ozaki DA, Sempowski GD, Rhein ME, Hale LP, Le Deist F, Alexieff MJ, Li J, Hauser ER, Haynes BF, Rice HE, Skinner MA, Mahaffey SM, Jaggers J, Stein LD, Mill MR. Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. Blood. 2003 Aug 1;102(3):1121-30. doi: 10.1182/blood-2002-08-2545. Epub 2003 Apr 17.
Results Reference
background
PubMed Identifier
23607606
Citation
Chinn IK, Milner JD, Scheinberg P, Douek DC, Markert ML. Thymus transplantation restores the repertoires of forkhead box protein 3 (FoxP3)+ and FoxP3- T cells in complete DiGeorge anomaly. Clin Exp Immunol. 2013 Jul;173(1):140-9. doi: 10.1111/cei.12088.
Results Reference
background
PubMed Identifier
20832849
Citation
Chinn IK, Olson JA, Skinner MA, McCarthy EA, Gupton SE, Chen DF, Bonilla FA, Roberts RL, Kanariou MG, Devlin BH, Markert ML. Mechanisms of tolerance to parental parathyroid tissue when combined with human allogeneic thymus transplantation. J Allergy Clin Immunol. 2010 Oct;126(4):814-820.e8. doi: 10.1016/j.jaci.2010.07.016. Epub 2010 Sep 15.
Results Reference
background
PubMed Identifier
17284531
Citation
Markert ML, Devlin BH, Alexieff MJ, Li J, McCarthy EA, Gupton SE, Chinn IK, Hale LP, Kepler TB, He M, Sarzotti M, Skinner MA, Rice HE, Hoehner JC. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood. 2007 May 15;109(10):4539-47. doi: 10.1182/blood-2006-10-048652. Epub 2007 Feb 6.
Results Reference
result
PubMed Identifier
20236866
Citation
Markert ML, Devlin BH, McCarthy EA. Thymus transplantation. Clin Immunol. 2010 May;135(2):236-46. doi: 10.1016/j.clim.2010.02.007. Epub 2010 Mar 16.
Results Reference
result
PubMed Identifier
18557726
Citation
Markert ML, Devlin BH, Chinn IK, McCarthy EA, Li YJ. Factors affecting success of thymus transplantation for complete DiGeorge anomaly. Am J Transplant. 2008 Aug;8(8):1729-36. doi: 10.1111/j.1600-6143.2008.02301.x. Epub 2008 Jun 28.
Results Reference
result
Citation
Markert ML and Devlin BH. Thymic reconstitution (in Rich RR, Shearer WT, Fleischer T, Schroeder HW, Weyand CM, Frew A, eds., Clinical Immunology 3rd edn., Elsevier, Edinburgh) p 1253-1262, 2008.
Results Reference
result
PubMed Identifier
18424759
Citation
Markert ML, Li J, Devlin BH, Hoehner JC, Rice HE, Skinner MA, Li YJ, Hale LP. Use of allograft biopsies to assess thymopoiesis after thymus transplantation. J Immunol. 2008 May 1;180(9):6354-64. doi: 10.4049/jimmunol.180.9.6354.
Results Reference
result
PubMed Identifier
18035553
Citation
Hudson LL, Louise Markert M, Devlin BH, Haynes BF, Sempowski GD. Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection. Semin Immunol. 2007 Oct;19(5):297-309. doi: 10.1016/j.smim.2007.10.002. Epub 2007 Nov 26.
Results Reference
result
Citation
Markert ML, Devlin BH, McCarthy EA, Chinn IK, Hale LP. Thymus Transplantation in Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features. Eds Lavinin C, Moran CA, Morandi U, Schoenhuber R. Springer-Verlag Italia, Milan, 2008, pp 255-267.
Results Reference
result
PubMed Identifier
19066739
Citation
Markert ML, Devlin BH, Chinn IK, McCarthy EA. Thymus transplantation in complete DiGeorge anomaly. Immunol Res. 2009;44(1-3):61-70. doi: 10.1007/s12026-008-8082-5.
Results Reference
result
PubMed Identifier
21565561
Citation
Li B, Li J, Devlin BH, Markert ML. Thymic microenvironment reconstitution after postnatal human thymus transplantation. Clin Immunol. 2011 Sep;140(3):244-59. doi: 10.1016/j.clim.2011.04.004. Epub 2011 Apr 16.
Results Reference
result
PubMed Identifier
23914737
Citation
Ciupe SM, Devlin BH, Markert ML, Kepler TB. Quantification of total T-cell receptor diversity by flow cytometry and spectratyping. BMC Immunol. 2013 Aug 6;14:35. doi: 10.1186/1471-2172-14-35.
Results Reference
result

Learn more about this trial

Thymus Transplantation Dose in DiGeorge #932

We'll reach out to this number within 24 hrs